GTC
ALNY icon

Ghost Tree Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ghost Tree Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-68,400
Closed -$16.6M – 57
2024
Q2 		$16.6M Buy
+68,400
New +$10.8M 5.2% 2

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's ALNY Position: Q3 2024 in Review

Ghost Tree Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 22,500 shares — an estimated $5.47M sold.

Ghost Tree Capital first reported a position in ALNY in Q2 2014 and held it in 17 quarters. The position peaked at $20.7M in Q2 2018. 566 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Ghost Tree Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 22,500 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $5.47M.
  • Ghost Tree Capital first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 17 quarters.
  • Ghost Tree Capital's Alnylam Pharmaceuticals position peaked at $20.7M in Q2 2018.
  • 566 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.